
Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock is trading higher on Wednesday, with apparently no news to justify the movement.
This week, Sarepta will present data from its gene therapy, delandistrogene moxeparvovec, for Duchenne muscular dystrophy (DMD).